Home

About us


IRDiRC is a consortium of research funding agencies and interested parties acting to accelerate research through collaborations

Objective 2020: 200 new therapies

/>
Follow the progress towards developing and authorising 200 new medicinal products to treat rare diseases by the year 2020.

Objective 2020: identify all genes


Follow the progress towards developing a diagnostic test to identify most rare diseases by the year 2020.

Become IRDiRC Recommended


A label to highlight key resources to accelerate research on rare diseases. Access the application form for “IRDiRC Recommended”.

State of Play of Research Report

State_of_Play
Read the analysis by IRDiRC of recent major research initiatives and outcomes, and of identified trends likely to shape the future

Matchmaker Exchange Task Force

MatchmakerExchange

IRDiRC-Global Alliance Matchmaker Exchange aims to provide data sharing tools to match unsolved genome/exome sequence cases

Patient Relevant/Related Outcome Measures Task Force

PROM
The development and adoption of patient-relevant and -reported outcome measures are instrumental in accelerating R&D

Small Population Clinical Trials Task Force

SPCT
Collaborative effort on adaptive design, statistical methods and acceptability of new methods in small population clinical trials

Machine Readable Consent Task Force

Computer_readable_consent_form
To make the most of clinical data sources worldwide, accessing patient consent is crucial to share data and improve research participation.

Data Mining-Repurposing Task Force

Data_mining
Exploiting existing data and knowledge is essential to identify new therapeutic targets and to repurpose drugs.